Biogen Defends Controversial Alzheimer's Drug as FDA Calls for Probe
Biogen's new — and controversial — Alzheimer's drug, Adhulem, made a modest $2 million in revenue in the first several weeks after its...
Full Article
Biogen Defends Controversial Alzheimer's Drug as FDA Calls for Probe
Motley Fool
0 shares
1 views
You might like
Related news coverage
FDA Narrows Guidance On New Alzheimer's Drug Amid Criticism
Newsy
Watch VideoThe acting head of the Food and Drug Administration on Friday called for a government investigation into highly unusual..
-
Private insurers decline to cover Biogen's new Alzheimer's drug in escalating standoff
Upworthy
-
FDA seeks probe into its talks with Biogen before Alzheimer’s drug approval
Indian Express
-
FDA head urges probe of agency’s dealings with maker of controversial Alzheimer’s drug
Washington Post
-
FDA calls for probe of staff involved in divisive Alzheimer’s approval
FT.com
Advertisement
More coverage
FDA head calls for inquiry into Alzheimer's drug review
SeattlePI.com
WASHINGTON (AP) — The acting head of the Food and Drug Administration on Friday called for a government investigation into highly..
-
Biogen FDA probe on Alzheimer's drug unlikely to have `tangible' impact, analyst says
SeekingAlpha
-
FDA head calls for probe into Alzheimer's drug review
SeattlePI.com
-
Biogen tumbles as FDA chief calls for a probe on Alzheimer’s drug approval
SeekingAlpha
-
FDA calls for investigation into controversial Alzheimer's drug approval
Upworthy